<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187224</url>
  </required_header>
  <id_info>
    <org_study_id>1603017361</org_study_id>
    <secondary_id>24330</secondary_id>
    <nct_id>NCT02187224</nct_id>
  </id_info>
  <brief_title>Progesterone Effect on Individuals Diagnoses With AD and PTSD.</brief_title>
  <official_title>Progesterone Treatment in Reducing Trauma and Alcohol Induced Craving in Individuals Diagnoses With Alcohol Dependence (AD) and Post-tramatic Stress Disorder (PTSD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized control trial with 36 participants diagnosed with post-traumatic stress&#xD;
      disorder (PTSD) and comorbid alcohol dependence. Participants will be randomized to receive&#xD;
      either progesterone (200 mg. bid) or placebo in identical looking capsules for three days.&#xD;
&#xD;
      One goal of this research study is to test if progesterone is more effective than placebo in&#xD;
      reducing craving after exposure to trauma cues and alcohol cues in a laboratory paradigm&#xD;
      among men and women with AD and PTSD. We hypothesize that progesterone in comparison to&#xD;
      placebo will significantly reduce craving for alcohol in response to trauma cues alone and in&#xD;
      combination with alcohol cues in individuals with AD and PTSD.&#xD;
&#xD;
      A second goal is to examine if there are gender differences in progesterone effects on stress&#xD;
      and alcohol cue-induced craving. We hypothesize that the effects of progesterone on stress&#xD;
      and craving will be stronger in women than in men. Participants will be recruited primarily&#xD;
      through advertisement, but also through the clinical facilities at the VA and from other&#xD;
      collaborators.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">September 8, 2021</completion_date>
  <primary_completion_date type="Actual">September 8, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale - Craving (VASC)</measure>
    <time_frame>Test day</time_frame>
    <description>Will be used to document the participants degree of craving for alcohol moment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>State Trait Anxiety Inventory (STAI-6)</measure>
    <time_frame>Test day</time_frame>
    <description>Will be used to document the participants degree of anxiety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Post-Traumatic Stress Disorder (PTSD)</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the three days prior to each test day every participant in this arm will receive progesterone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the three days prior to each test day every participant in this arm will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Progesterone)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ages 18 to 45;&#xD;
&#xD;
          2. Current diagnosis of AD and PTSD;&#xD;
&#xD;
          3. Drink regularly are not in an active phase of alcohol withdrawal;&#xD;
&#xD;
          4. Not at risk for suicide;&#xD;
&#xD;
          5. Not taking regularly psychoactive drugs including anxiolytics and antidepressants;&#xD;
&#xD;
          6. For women, have regular menses every 25-35 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current SCID diagnosis of any psychotic disorder;&#xD;
&#xD;
          2. Substance dependence (other than alcohol and nicotine) in the past 30 days;&#xD;
&#xD;
          3. Current unstable medical condition;&#xD;
&#xD;
          4. Positive test results at more than one baseline appointment on urine drug screens&#xD;
             conducted for opiates, cocaine, marijuana, benzodiazepines, and barbiturates; for&#xD;
             women, amenorrhea, use of oral contraceptives;&#xD;
&#xD;
          5. Known allergy to progesterone or peanuts (vehicle for micronized progesterone);&#xD;
&#xD;
          6. History of thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or&#xD;
             Bleeding disorders, heart disease, diabetes or history of stroke.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Ralevski, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healtcase System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Post-Traumatic stress disorder (PTSD)</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

